Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Top Cited Papers
- 30 November 2018
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 393 (10167), 156-167
- https://doi.org/10.1016/s0140-6736(18)31999-8
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp and Dohme
This publication has 25 references indexed in Scilit:
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour siteRadiotherapy and Oncology, 2011
- Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-upAnnals of Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapiesCancer, 2008
- A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck CancerCancer Investigation, 2007
- Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckCancer, 2005
- Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialAnnals of Oncology, 2005
- Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancerEuropean Journal Of Cancer, 2004
- The Efficiency of Cox's Likelihood Function for Censored DataJournal of the American Statistical Association, 1977